Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of the Combination of Sintilimab With Platinum-doublet Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients

NCT07138755 is registered in ClinicalTrials.gov with The Third Xiangya Hospital of Central South University as lead sponsor.

NCT NCT07138755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07138755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of the Combination of Sintilimab With Platinum-doublet Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients
Lead sponsor
The Third Xiangya Hospital of Central South University
Phase
Phase 2
Overall status
Recruiting
Start date
August 29, 2025
Completion date
September 30, 2030
Enrollment
35 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

adaptive radiotherapy, nsclc, sintilimab